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prices fixed by negociation between the Comité Economique des Produits de Santé 
and the manufacturers. The average discount ranges from 11% to 73%. The aver-
age EMI varies between 1.42 and 2.69 € excluding value added tax (EVAT) per 1000 
international units and between 0.09 and 0.22 € EVAT per microgram according 
to the medicinal product. The average amount refunded to HF can be estimated 
at january 1, 2012 at 3.37 M€ , or 22.6% of the total budget. We assessed annual 
prices trends based on starting dates of contract, and we could figure out EMI 
trends. According to the product, the EMI quickly decline, remain broadly stable 
or increase. ConClusions: Many of top-selling biologics are due to lose patent 
protection over the next years. The emergence of competition in pharmaceutical 
market contributes to better control expenditure in our health system. The great 
potential for cost savings concerning erythropoietic factors in our study could be 
investigated in other class of medicinal products.
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objeCtives: To assess the economic impact of Fentanyl Buccal Tablet for the 
management of breakthrough cancer pain (BTcP) in Spain Methods: A 4-year 
budget impact model was developed for the period 2012-2015 for patients with 
BTcP from the perspective of the Spanish National Health System. BTcP products 
included in this model were rapid onset opioids containing fentanyl products 
(buccal, sublingual, or nasal transmucosal). Prevalence data on cancer, BTcP, opi-
oid use and number of BTcP episodes were obtained from literature. Input data 
on direct medical resources associated with opioid use and opioide-induced side 
effects (OISEs) were obtained by consulting experts in oncology from different 
Spanish hospitals. Resource utilisation included drugs, medical and emergency 
visits, other non-pharmacological treatments and the treatment of OISEs. Unit 
costs were obtained from literature and a 3% discount rate was applied to costs. 
Based on the unit costs for drugs and medical resources the annual BTcP treatment 
costs per patient associated with each product were determined, to estimate the 
overall budget impact based on the total treatment population and the percentage 
of drug utilisation associated with each product Results: Patients treated with 
oral opioids for BTcP was estimated at 23,291 in 2012 with an increase up to 23,413 
in 2015. The average annual budget savings with an increase of Fentanyl Buccal 
Tablet, Fentanyl Sublingual Tablet and Intranasal Fentanyl Spray and a decrease 
of Oral Transmucosal Fentanyl Citrate, was estimated at € 2.6 million over the 
next four years ConClusions: The increase in the use of Fentanyl Buccal Tablet 
leads to overall savings in the budget impact for the Spanish NHS. Although the 
economic impact of BTcP treatment showed to increase over the next four years 
due to population growth the average annual cost per patient reduced with € 29 
by the increase in the use of Fentanyl Buccal Tablet.
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eCoNomIC ImPaCt of deNosumaB for skeletal related eveNt 
PreveNtIoN IN PatIeNts wIth Breast CaNCer aNd BoNe metastasIs 
from a uNIted state maNaged Care orgaNIzatIoN PersPeCtIve
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objeCtives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in BrCa patients with BM to a 
MCO. Methods: An economic model was developed to estimate clinical and 
economic impact to a 1-million-member US MCO of introducing denosumab as 
bone-targeting agent (BTA) for prevention of SREs in BrCa patients with BM. Total 
number of patients receiving BTA was estimated based on disease prevalence and 
treatment eligibility in this population. The real-world SRE rates in ZA-treated 
patients were derived from a large commercial database and used together with 
the trial-based treatment effect for denosumab versus ZA to estimate the deno-
sumab SRE rate. Total number of SREs, total SRE management medical cost, BTA 
drug cost, and total cost were calculated. The impact of denosumab per-member-
per-month (PMPM) at increasing utilization rates was assessed by comparing to 
a scenario without denosumab, i.e., all patients received ZA. Additionally, impact 
of annual increase in denosumab use was conducted. Results: A total of 122 
BrCa patients with BM received BTA. In the scenario where all eligible patients 
receiving ZA, an annual total number of SREs was 155. An annual denosumab use 
of 20%, 35% or 45% resulted in 4.5%, 7.9%, and 10.2% reduction in total SREs and 
5.7%, 10.1%, and 12.9% reduction in medical costs of managing SREs, compared to 
all patients receiving ZA. The drug cost was partially offset by the reductions in 
the medical cost and the increase in total cost was minimal (2.4%-5.5%). The PMPM 
ranged $0.008-$0.017. Consecutive-year analysis showed $0.004 increase in PMPM 
with 10% denosumab utilization increase. ConClusions: Due to superior efficacy 
of denosumab versus ZA in SRE prevention in BrCa patients with BM, increased 
denosumab use results in medical cost reduction in a US MCO. Overall, denosumab 
provides additional clinical value with limited budget impact.
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objeCtives: Obinutuzumab is the first, glycoengineered type II antibody dem-
onstrating increased Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and 
background scenario the cost was 29,639.22€ . In terms of total costs the background 
scenario had a lower cost on average until the year 2009. ConClusions: Early detec-
tion of breast cancer improves survival prognosis and decreases treatment costs for 
each detected cancer. In the future, the costs of the early detection program will be 
balanced by the savings in treatment costs.
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objeCtives: Metastatic prostate cancer (MPC) results from the spread of cancer to 
distant parts of the body and is associated with markedly decreased survival. First 
line therapy for prostate cancer involves androgen deprivation, however most MPC 
patients progress in spite of castration levels of testosterone. A recently approved 
infusion product, Radium Ra 223 dichloride (Radium-223), has been introduced in 
the U.S. market adding to concerns about the costs for end-stage treatments. We 
sought to estimate the budget impact of Radium-223 on infusion center expenses 
in the U.S. Methods: We developed a financial model to estimate budget impact 
from a hospital-based infusion center perspective. Using data from the U.S. Census, 
SEER, and the Premier Perspective Database, we estimated the eligible population 
using a theoretical hospital’s catchment area. We modeled use, treatment costs 
and reimbursement for three radiopharmaceuticals (Radium-223, Samarium-153, 
and Strontium-89) and two common chemotherapies (docetaxel and cabazitazel) 
in terms of drug cost, infusions, and laboratory monitoring. Reimbursement for 
these treatments was estimated at both commercial and Medicare rates using the 
Average Sale Price and relevant Common Procedural Technology codes. We calcu-
lated total cost and reimbursement for one year with the current utilization from 
Premier and then estimated the incremental net budget impact associated with 
adoption of Radium-223 at 1, 3, and 5% of patients. Results: In a catchment area 
of 1 million lives, an estimated 45 MPC patients with non-visceral bone metastases 
would be treated with current agents and incur approximately $500,000 in treat-
ment costs for radiopharmaceuticals and chemotherapy. Adding Radium-223 to the 
treatment mix and assuming adoption rates of 1% to 5%, the annual net impact 
on the infusion center budget would range from $600 to $3,000. ConClusions: 
Radium-223 presents a new treatment option for MPC patients with non-visceral 
bone metastases and a positive net impact for infusion centers.
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objeCtives: Ovarian cancer (OC) is one of the most lethal gynecologic cancers 
worldwide. According to Brazilian Institute of Cancer (INCA), 6,190 new OC cases 
were estimated in 2012. During the last 15 years, carboplatin plus paclitaxel (CP) 
has been established as front-line (FL) standard of care therapy for advanced ovar-
ian cancer, with no significant advances in treatment ever since. Bevacizumab 
(Bev) in combination with CP was approved in Brazil for FL treatment of advanced 
epithelial OC on May/2013. Therefore, this study aimed to estimate the economic 
impact of bevacizumab reimbursement for advanced OC in Brazilian Supplementary 
Healthcare System. Methods: The potential number of eligible patients for CP + 
Bev in FL therapy for advanced OC was estimated following an epidemiologic 
approach. It was assumed that Supplementary Healthcare System attendance 
accounts for 40% of all patients. Additional drug costs and infusion fees were evalu-
ated. The ex-factory price (VAT 18%) and labeled dose were considered. Average 
therapy duration of CP + bevacizumab was 15 months based on GOG-0218 trial. Costs 
were reported in Brazilian Reais (BRL1.00≈USD0.44; Jun/2013). A total health assis-
tance budget of BRL 88.1 billion was forecasted for 2013, based on the last updated 
data from Brazilian National Regulatory Agency for Private Health Insurance and 
Plans (ANS). Results: A total of 1,287 eligible cases in CP + Bev FL therapy for 
advanced OC are expected in 2013 in the private setting. Adding bevacizumab to 
the treatment of all these potential patients would yield an increase of BRL 267 
million, corresponding only to an increment around 0.30% on health assistance 
expenses. ConClusions: Treating all eligible FL advanced OC patients with CP + 
Bev will potentially result in a low impact in Supplementary Healthcare System 
budget, associated to unprecedented clinical benefits for this population with a 
high medical unmet need.
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objeCtives: The patent expiries of leading biologic products and development of 
biosimilars create opportunities for cost saving. The french public health policies 
has established a complementary means encouraging heathcare facilities (HF) to 
save money : the ‘‘écart médicament indemnisable’’ (EMI). We explored the evalu-
ation of EMI on the erythropoietic factors class. Methods: We’ve carried out a 
comparative study in french HF, representing about 65% of national hospital beds, 
on the price of erythropoietic factors. The data have been collected on procurement 
procedures operative as at January 1, 2012. Results: A total of 25 care facilities or 
group of care facilities agreed to participate in the study. The overall sales turnover 
reached 15 millions euros (M€ ). All HF granted a discount from 5% to 69% on the 
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objeCtives: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate com-
prised of the microtubule inhibitory cytotoxic agent DM1 and trastuzumab which, in 
addition to its antitumor properties, targets T-DM1 to HER2–overexpressing cells. The 
overall safety profile of T-DM1 was investigated in the phase III EMILIA trial (com-
paring T-DM1 [n= 496] to capecitabine plus lapatinib [CAP+LAP, n= 495]) in patients 
with HER2-positive locally advanced or metastatic breast cancer (MBC) previously 
treated with trastuzumab and a taxane, and the phase II TDM4450g trial (comparing 
T-DM1 [n= 67] to trastuzumab plus docetaxel [TRAZ+DOCE, n= 70]) in patients with 
previously untreated MBC. Both trials demonstrated clinically meaningful differ-
ences between T-DM1 and its comparators. The objectives were to estimate and 
compare the Canadian costs of managing the treatment-related adverse events 
(AEs) of T-DM1 as reported in the two trials, from the perspective of Canadian 
public payers. Methods: An Excel based spreadsheet model was utilized for the 
analysis. Costing information was obtained from the literature, clinical experts, and 
Canadian standard costing sources. Costs were reported as 2012 CAD. The AEs that 
were considered were all treatment-related grade ≥ 3 AEs as well as grade 2 AEs that 
occurred in ≥ 5% of patients in both arms of either study. Results: The manage-
ment of treatment-related AEs as reported in the EMILIA trial resulted in higher per 
patient costs ranging from $3,060 - $10,499 for CAP+LAP versus $1,376 - $2,463 for 
T-DM1, yielding savings of $1,684-$8,036. In the TDM4450g trial, the management 
of treatment-related AEs resulted in higher per patient costs ranging from $5,124 
- $27,617 for TRAZ+DOCE versus $798 - $2,215 for T-DM1, yielding savings of $4,326-
$25,402. ConClusions: This analysis demonstrated that utilizing T-DM1 for the 
management of HER2-positive metastatic breast cancer results in significant cost 
savings of related AEs management due to the improved safety profile compared 
to CAP+LAP and TRAZ+DOCE.
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objeCtives: Stereotactic radiation therapy is an innovative technique with high 
therapeutic potential due to excellent local control and increased survival rate. A 
cost analysis investigating stereotactic radiation therapy modalities either with lin-
ear accelerator (Cone Beam Computed Tomography (CBCT), Exac-trac) or Cyberknife 
was conducted. Methods: The cost-analysis was performed prospectively based 
on a multicenter study. Patients included were treated for lung carcinoma (T1-T2, N0, 
M0). Cost calculations were strictly based on a micro costing approach according to 
the hospitals’ point of view. Only direct costs were taken into account. Productivity 
losses of personnel involved in the process, costs of administrative personnel, costs 
of logistics and general management were not taken into account. Time horizon 
included radiation therapy (preparation for radiation therapy and the fraction itself). 
All costs were given in 2011 euros. Uncertainty was captured by one-way and proba-
bilistic sensitivity analyses using a non-parametric bootstrap method. Results: 
113 patients were enrolled in 11 French centers from April 2009 to December 2011. 
98 economic questionnaires were exploitable. The costs of preparation for stereo-
tactic radiation therapy were 430€ (SD: 101€ ) with Cyberknife and 433€ (SD: 199€ ) 
with linear accelerator. When required, costs of implementation of fiducial markers 
with one/two days of inpatient care were 1,619€ . The costs of stereotactic radia-
tion therapy (all fractions included) were 1,811€ (SD: 760€ ) with Cyberknife and 
817€ (SD:403€ ) with linear accelerator. Costs per fraction were 550€ (SD: 224€ ) with 
Cyberknife and 201€ (SD: 97€ ) with linear accelerator. Depreciation periods of the 
accelerator played a major role in costs. ConClusions: This is to our knowledge 
the first study highlighting costs incurred by different stereotactic radiation therapy 
modalities in lung cancers. Cost-effectiveness studies have to be conducted in order 
to shed further light on which modality to focus on.
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Campone M.1, Yang H.2, Faust E.2, Kageleiry A.2, Signorovitch J.2, Zhang J.3, Gao H.3
1Institut de Cancérologie de l’OUEST, Saint Herblain-Nantes Cedex, France, 2Analysis Group, Inc., 
Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
objeCtives: Everolimus plus exemestane (EVE+EXE) recently received approval for 
the treatment of patients with HR+/HER2- advanced breast cancer that recurs or 
progresses during/after non-steroidal aromatase inhibitors. This study was designed 
to evaluate the expected costs of managing adverse events during EVE+EXE therapy 
and single-agent chemotherapy in the western European region. Methods: An 
economic model was developed to estimate per-patient cost of managing adverse 
events for patients receiving EVE+EXE or chemotherapies. Adverse event rates for 
EVE+EXE were collected from the phase III BOLERO-2 trial. Adverse event rates for 
capecitabine, docetaxel, and doxorubicin chemotherapies were collected from 
published clinical trial data. Grade 3/4 adverse events with at least 2% prevalence 
during any of these treatments were included in the study. The adverse event rate 
direct cell death compared with rituximab (Rtx) and is pending regulatory approval 
(in combination with chlorambucil (Clb)) for the treatment of patients with pre-
viously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab+Clb has 
shown > 85% reduction in the risk of progression, relapse or death in comparison 
to treatment with Clb alone (HR 0.14), a broadly accepted treatment option for many 
patients with co-existing medical conditions. In a majority of markets the health 
economic consequences will be assessed in terms of affordability. Methods: A 
health economic model was developed analyzing the cost impact of obinutuzumab 
on further lines of treatment due to the number of reduced refractory patients com-
pared to Clb and Rtx. Market share information for obinutuzumab, ofatumumab, 
Rtx, Clb and Bendamustine and the different relevant combinations were entered 
for Germany and Canada (Ontario province only). Results: Based on a 39% reduc-
tion in numbers of refractory patients treated with obinutuzumab+Clb compared 
to Rtx+Clb cost savings per year per patient (PYPP) for further line treatments in 
Canada (Ontario) range between Ca$950 and Ca$3,091, which leads to maximum 
cost savings for the whole eligible population (401 patients) up to $Ca1,239,491. 
In Germany the cost savings range PYPP between € 2,556 and € 8,318, which leads 
to maximum cost savings for the whole eligible population (1,302 patients) up to 
€ 10,830,036. The big difference in the cost savings PYPP between the two coun-
tries is mainly due to the different market share assumptions for ofatumumab. 
Key cost drivers were treatment duration and price/cost of further line treatments. 
Scenario analyses on cost, efficacy and market share data confirmed these find-
ings. ConClusions: Obinutuzumab+Clb shows significant patient-relevant clini-
cal benefits and potential cost savings in further line treatments in patients with 
previously untreated CLL.
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objeCtives: To assess the cost-effectiveness of the new transdermal therapeutic sys-
tem (TTS) of fentanyl and subcutaneous injections (SIs) of morphine hydrochloride in 
the treatment of chronic pain and predict potential budget impact of the implementa-
tion of fentanyl TTS in routine clinical practice. Methods: The pharmacoeconomic 
model was developed based on the results of Russian observational study, included 
45 patients with terminal cancer: 25 patients received fentanyl TTS and 20 – SIs of 
morphine. At the first stage, the cost-effectiveness ratios (CERs) of therapies during 
the first month was measured as total costs of medicines and expenses for ambulance 
services for acute pain relief per one patient without side-effects. At the second stage, 
the CERs of therapies during subsequent three months was measured as costs of 
medicines per one unit of pain intensity (PI) reduction (visual pain scale). Results: 
During the first month of therapy the frequency of ambulance use was significantly 
lower in patients received fentanyl TTS (0.32 vs 1.05 per one patient per week in the 
morphine group), this was reflected in lower total costs (12 611, 42 RUB and 23,037.54 
RUB per one patient, respectively). Patients in the fentanyl TTS group were less likely 
to have side effects. The estimated CERs for fentanyl TTS and SIs of morphine were 
13,001.46 RUB and 27,756.07 RUB per one patient without vomiting and 23,354.47 
RUB and 82,276.93 RUB per one patient without constipation, respectively. Long-term 
treatment with fentanyl TTS was resulted in decreased PI as compared to SIs of mor-
phine. The three-month CERs were 4,897.05 RUB and 7,869.30 RUB per one unit of PI 
reduction, respectively. ConClusions: The present study has demonstrated that 
administration of new transdermal therapeutic system of fentanyl has the better 
cost-effectiveness profile in the treatment of Russian cancer patients.
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objeCtives: Chemotherapy-induced neutropenia (CIN), a commonly-occurring 
adverse event in cancer patients undergoing chemotherapy, and particularly febrile 
neutropenia (FN), have potentially life-threatening and costly consequences. The 
standard of care for patients at risk of FN comprises prophylactic administra-
tion of recombinant granulocyte colony-stimulating factor (G-CSF) with pegfil-
grastim, a long-acting formulation of G-CSF, and the most widely used in Europe. 
Lipegfilgrastim is a novel, pegylated and glycosylated long-acting G-CSF designed 
for use in the same patient population as pegfilgrastim. We developed a model to 
estimate the economic impact over five years of managing G-CSF-eligible chem-
otherapy patients at risk of FN with lipegfilgrastim rather than pegfilgrastim in 
Scotland. Methods: The eligible patient population was estimated based on cancer 
incidence in Scotland and current uptake of G-CSF by patients initiating chemo-
therapy to prevent neutropenia. Drug, monitoring and event costs were taken from 
the British National Formulary, Unit Costs of Health and Social Care and Scottish 
National Tariff. As lipegfilgrastim was shown to be non-inferior to pegfilgrastim (in 
a phase III study in breast cancer patients), the efficacy and safety of pegfilgrastim 
and lipegfilgrastim were assumed to be identical. Non-statistically significant trends 
towards fewer neutropenic events and dose modifications with lipegfilgrastim were 
explored in scenario analyses. Results: The model estimated that 315 patients 
currently receive pegfilgrastim annually. A progressive increase in lipegfilgrastim 
uptake was associated with cost savings ranging from £2,814 in year 1 to £16,883 in 
year 5, totalling £61,904 over five years. Savings were attributable to the low drug 
acquisition cost of lipegfilgrastim. Using event rates from the pivotal phase III breast 
cancer study, scenario analyses suggested that using lipegfilgrastim instead of peg-
filgrastim generated savings of £145,312, avoided 81 neutropenic events (including 
11 occurrences of FN) and 50 dose modifications, and caused 34 additional treat-
ment-emergent adverse events. ConClusions: Lipegfilgrastim was cost-saving 
compared with pegfilgrastim.
